Doctor visits for RSV are at a "very high" level in Mississippi. Health officials provide warning signs of RSV to look for in children, adults ...

Respiratory syncytial virus is the leading cause of hospitalization among U.S. infants. A vaccine, nirsevimab, can reduce the ...

So, which respiratory virus invaded your cells? Several types of viruses could be the culprit: respiratory syncytial virus ...

Respiratory syncytial virus, or RSV, is a common virus that infects the nose, throat and lungs, according to the U.S. Centers ...

The RSVPreF vaccine is safe and demonstrates immunobridging to efficacy among adults aged 18 to 59 who are at high risk for ...

The federal Centers for Disease Control and Prevention recently endorsed a policy that encourages Americans to seize upon the ...

RSVpreF vaccination is effective against RSV-related lower respiratory tract disease among adults aged 60 years or older.

Flu cases are surging across the commonwealth but for the youngest Pennsylvanians, another potentially dangerous respiratory virus is spreading quickly.

COVID-19 (S Protein) is under clinical development by Vaxart and currently in Phase II for Coronavirus Disease 2019 (COVID-19).

ASC-60 is under clinical development by Sagimet Biosciences and currently in Phase I for Solid Tumor. According to GlobalData, Phase I drugs for Solid Tumor have a 69% phase transition success rate ...

Respiratory virus data included in the interactive data application is up-to-date as of December 28, 2024. Among its new features, the dashboard now includes RSV Severe Outcomes data.

Here are five key risk factors to know. Grandparents and grandkids share a special bond, but during respiratory virus season, older adults need to take extra care. People ages 65 and older are at ...